Lv21
102 积分 2025-05-12 加入
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study
10天前
已完结
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience
10天前
已完结
Pomalidomide, Cyclophosphamide and Dexamethasone ( PCd ): Outcomes in Patients With Double‐ or Triple‐Refractory Multiple Myeloma
11天前
已完结
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma
11天前
已完结
Bortezomib-Cyclophosphamide-Dexamethasone for Relapsing Multiple Myeloma
12天前
已完结
Combined Treatment of Bortezomib, Continuous Low-Dose Cyclophosphamide and Dexamethasone Followed By One Year of Maintenance Treatment for Refractory or Relapsed Multiple Myeloma Patients: A Prospective Phase II Study
13天前
已关闭
Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide
13天前
已完结
Bortezomib in combination with intermediate‐dose dexamethasone and continuous low‐dose oral cyclophosphamide for relapsed multiple myeloma
14天前
已完结
Phase I dose-escalation study of cyclophosphamide combined with bortezomib and dexamethasone in Japanese patients with relapsed and/or refractory multiple myeloma
14天前
已完结
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse
14天前
已完结